LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

HANGZHOU, China, May 16, 2023 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical...

Related Keywords

Hangzhou ,Zhejiang ,China ,Australia ,Peking ,Beijing ,Xiaofeng Zeng ,Henry Wu ,Department Of Rheumatology ,Lynk Pharmaceuticals Co Ltd ,Lynk Pharmaceuticals ,Drug Evaluation ,Disease Modifying Anti Rheumatic ,Professor Xiaofeng Zeng ,Peking Union Medical College Hospital ,Chinese Academy ,Ankylosing Spondylitis ,Atopic Dermatitis ,Chief Development Officer ,